An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles
Source abstract
Abstract
The rhodamine B (RhB) covalently grafted SBA-15-structured mesoporous silica nanoparticles (MSNs-RhB) of high surface area (750 m(2) g(-1)), large pore volume (0.7 cm(3) g(-1)), uniform particle size (about 400 nm) and positively charged surface (29.6 +/- 5.0 mV), has been developed as a drug delivery system (SAB@MSNs-RhB) for anti-ROS (reactive oxygen species)/hepatic fibrosis by loading a negatively charged drug salvianolic acid B (SAB). The dosage formulation SAB@MSNs-RhB effectively protected the loaded drug SAB from decomposition. The multi-release experimental results showed that SAB@MSNs-RhB exhibited an outstanding SAB sustained-release property, and relatively high SAB release rates and concentrations in a long term after the consumption of previously released SAB as compared to SAB loaded MSNs (SAB@MSNs) of negatively charged surface (-31.1 +/- 2.6 mV). The influences of the drug concentration, incubation time, drug formula and drug carrier on the ROS level, proliferative activity and cytotoxicity of LX-2 cells were evaluated. The results showed that the inhibiting effect of SAB@MSNs-RhB on the ROS level and proliferative activity of LX-2 cells was more remarkable than free SAB in a long term (72 h), and became more intensive with the increase of the sample concentration and the incubation time. SAB@MSNs-RhB enhanced the cellular drug uptake, the drug bioaccessability and efficacy for anti-ROS/hepatic fibrosis via the nanoparticles-mediated endocytosis and the sustained release of the drug. There was no visible cytotoxicity of free SAB, MSNs-RhB and SAB@MSNs-RhB against LX-2 cells in a broad concentration range (0.5-100 microm) and incubation time periods up to 72 h. The blood compatibility of the carrier MSNs-RhB was evaluated by investigating the hemolysis and coagulation behaviors in a broad concentration range (50-500 microg mL(-1)) under in vitro conditions. The results suggested that MSNs-RhB possessed good blood compatibility.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Liver physiology and pathology · Pediatric Hepatobiliary Diseases and Treatments · Gallbladder and Bile Duct Disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (49)
Show source-provided references
1. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation10.1111/j.1478-3231.2007.01527.x ↗
2. Chinese medicines as a resource for liver fibrosis treatment10.1186/1749-8546-4-16 ↗
3. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats10.1016/j.taap.2009.10.002 ↗
4. Progress of research on mechanism of salvia miltiorrhiza and its chemical ingredients against liver fibrosis10.3736/jcim20040223 ↗
5. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B
6. Mechanisms of phospholipid complex loaded nanoparticles enhancing the oral bioavailability10.1021/mp900274u ↗
7. Enhanced oral bioavailability of salvianolic acid B by phospholipid complex loaded nanoparticles
8. A new property of MCM-41: drug delivery system10.1021/cm0011559 ↗
9. Mesoporous materials for drug delivery10.1002/anie.200604488 ↗
10. Hollow spheres of mesoporous aluminosilicate with a three-dimensional pore network and extraordinarily high hydrothermal stability10.1021/nl034134x ↗
11. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins10.1021/ja0719780 ↗
12. Photocontrolled reversible release of guest molecules from coumarinmodified mesoporous silica10.1038/nature01362 ↗
13. pH-responsive carrier system based on carboxylic acid modified mesoporous silica and polyelectrolyte for drug delivery10.1021/cm051198v ↗
14. Stimuli-responsive controlled drug release from a hollow mesoporous silica sphere/polyelectrolyte multilayers core-shell structure10.1002/anie.200501500 ↗
15. Construction of a pH-driven supramolecular nanovalve10.1021/ol0612509 ↗
16. Control of drug release through the in situ assembly of stimuli-responsive ordered mesoporous silica with magnetic particles10.1002/cphc.200700362 ↗
17. Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles10.1002/anie.200501819 ↗
18. Temperature-controlled uptake and release in PNIPAM-modified porous silica nanoparticles10.1021/cm703363w ↗
19. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery10.1021/nn800072t ↗
20. Mesoporous silica nanoparticles for drug delivery and biosensing applications10.1002/adfm.200601191 ↗
21. Enzyme immobilization in MCM-41 molecular sieve10.1016/S1381-1177(96)00017-3 ↗
22. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent10.1021/ja046275m ↗
23. Well-ordered mesoporous silica nanoparticles as cell markers10.1021/cm051014c ↗
24. Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems10.1039/b701744h ↗
25. Pure-silica zeolites (porosils) as model solids for the evaluation of the physicochemical features determining silica toxicity to macrophages10.1021/tx990169u ↗
26. Mesoporous materials for encapsulating enzymes10.1016/j.nantod.2009.02.001 ↗
27. Monodispersed mesoporous silica nanoparticles with very large pores for enhanced adsorption and release of DNA10.1021/jp807956r ↗
28. Synthesis and characterization of positive-charge functionalized mesoporous silica nanoparticles for oral drug delivery of an anti-inflammatory drug10.1002/adfm.200800521 ↗
29. Storage and release of ibuprofen drug molecules in hollow mesoporous silica spheres with modified pore surface10.1016/j.micromeso.2005.06.015 ↗
30. A facile route to synthesize magnetic particles within hollow mesoporous spheres and their performance as separable Hg2+ adsorbents10.1039/b802857e ↗
31. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury10.1074/jbc.275.4.2247 ↗
32. Oxidative stress-related molecules and liver fibrosis10.1016/S0168-8278(01)00142-8 ↗
33. Oxidative stress, plant-derived antioxidants and liver fibrosis10.1055/s-2002-26761 ↗
34. Rhodamine B-co-condensed subsphaeroidal SBA-15 nanoparticles: facile co-condensation synthesis and excellent fluorescence features10.1039/b900357f ↗
35. Bottom-up tailoring of nonionic surfactant-templated mesoporous silica nanomaterials by a novel composite liquid crystal templating mechanism10.1039/b907266g ↗
36. Effect of salvianolic acid B on oxidative damage in primary hepatocytes and hepatic stellate cells10.1016/j.jep.2005.10.021 ↗
37. Stability of salvianolic acid B in Danshen freeze-dried product injection
38. Ordered mesoporous microspheres for bone grafting and drug delivery10.1021/cm801649z ↗
39. Anti-fibrotic effects of Salvia miltiorrhiza on dimethylnitrosamine-intoxicated rats10.1007/s11373-004-8167-7 ↗
40. Intracellular localization and cytotoxicity of spherical mesoporous silica nano-/micro-particles10.1002/smll.200900923 ↗
41. The biocompatibility of mesoporous silicates10.1016/j.biomaterials.2008.07.007 ↗
42. Mesoporous silica nanoparticles for reducing hemolytic activity toward mammalian red blood cells10.1002/smll.200800926 ↗
43. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses10.1016/j.biomaterials.2009.10.046 ↗
44. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity10.1021/ja910846q ↗
45. Testing of modified zeolite hemostatic dressings in a large animal model of lethal groin injury10.1097/01.ta.0000240597.42420.8f ↗
46. Application of a zeolite hemostatic agent achieves 100% survival in a lethal model of complex groin injury in swine10.1097/01.TA.0000127763.90890.31 ↗
47. Oxide hemostatic activity10.1021/ja061717a ↗
48. Spherical bioactive glass with enhanced rates of hydroxyapatite deposition and hemostatic activity10.1002/smll.200600177 ↗
49. Degradable, antibacterial silver exchanged mesoporous silica spheres for hemorrhage control10.1016/j.biomaterials.2009.06.052 ↗